Amphastar Pharmaceuticals reportedly paid more than $100,000 to a private investigative firm to snoop on FDA officials they suspected of having a too-chummy relationship with a competitor drug maker. Amphastar insists it did nothing wrong, but Senate Finance Committee investigators are looking into the case. Law Professor Kevin Outterson, an authority on drug law and marketing, says it’s disturbing.
“I don’t know what is more disturbing: that Amphastar hired the private detectives or that they are unapologetic about it after being caught.”
Contact Kevin Outterson, 617-353-3103, email@example.com